In This Section      
 

Search Results

Title:
A Phase I Study of Intravaginally Administered Artesunate In Women with High Grade Cervical Intraepithelial Neoplasia (CIN2/3)
Protocol Number:
J1498
Phase:
Phase I
Physician:
Cornelia (Connie) Trimble
Sites:
Johns Hopkins Kimmel Cancer Center in Baltimore
Purpose:
Purpose Cervical dysplasia is caused by infection with a common virus, human papillomavirus (HPV). This study will test safety, tolerability and efficacy of Artesunate vaginal suppositories.
Eligibility:
Females over age 18 with CIN2/3 caused by high risk HPV Immune competent Weight over 50kg (110lb)
Treatment:
Subjects in this study will receive Artesunate vaginal suppositories before having a cone or a LEEP procedure at week 15, if it is still necessary. There are study specific blood samples and cervical swabs collected before and after the treatment, and at the time of surgery. The suppositories are provided at no cost in this trial.
Population:
Adult
Last Update
03/05/2019 05:03 AM